Correction to AbbVie Earnings Article
October 30 2020 - 10:05AM
Dow Jones News
AbbVie Inc.'s third-quarter revenue from its immunology
portfolio was $5.79 billion, a 14.8% increase year over year. That
result included revenue from AbbVie's Humira medication of $5.14
billion, a figure that rose 4.1% year over year. "AbbVie Logs 3Q
Sales Growth on Higher Immunology, Oncology Results," published at
8:07 a.m. ET, incorrectly said that immunology revenue increased
4.1%, to $5.14 billion.
(END) Dow Jones Newswires
October 30, 2020 09:50 ET (13:50 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Feb 2024 to Mar 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2023 to Mar 2024